Theravance Biopharma, Inc. Increase (Decrease) in Accounts Receivable
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Accounts Receivable of -$620.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-02-28
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-12-31 was -$86.00K.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-09-30 was -$145.00K.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-06-30 was $118.00K, a 91.92% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for the quarter ending 2019-03-31 was -$507.00K.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2019 was -$620.00K.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2018 was -$1.63M, a 201.62% decline from fiscal 2017.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2017 was $1.61M.
- Theravance Biopharma, Inc. increase (decrease) in accounts receivable for fiscal 2016 was -$1.28M, a 178.14% decline from fiscal 2015.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$231.00K derived: sum of 2 quarters · filed 2022-02-28 | -$113.00K derived: sum of 3 quarters · filed 2022-02-28 | -$620.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | -$145.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$27.00K derived: sum of 2 quarters · filed 2020-11-09 | -$534.00K 10-Q · filed 2020-11-09 | -$2.94M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$389.00K 10-Q · filed 2020-08-10 | -$2.79M derived: sum of 3 quarters · filed 2021-02-26 | -$3.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$507.00K 10-Q · filed 2020-05-08 | -$2.91M derived: sum of 2 quarters · filed 2021-02-26 | -$3.32M derived: sum of 3 quarters · filed 2021-02-26 | -$1.86M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$2.81M derived: sum of 2 quarters · filed 2021-02-26 | -$1.35M derived: sum of 3 quarters · filed 2021-02-26 | -$1.63M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$410.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $1.05M derived: sum of 2 quarters · filed 2019-11-08 | $771.00K 10-Q · filed 2019-11-08 | $1.45M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $1.18M 10-Q · filed 2019-08-05 | $1.86M derived: sum of 3 quarters · filed 2020-02-27 | $2.09M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$280.00K 10-Q · filed 2019-05-10 | $397.00K derived: sum of 2 quarters · filed 2020-02-27 | $627.00K derived: sum of 3 quarters · filed 2020-02-27 | $740.00K derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $907.00K derived: sum of 2 quarters · filed 2020-02-27 | $1.02M derived: sum of 3 quarters · filed 2020-02-27 | $1.61M 10-K · filed 2020-02-27 |
| 2017-09-30 | $230.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $343.00K derived: sum of 2 quarters · filed 2018-11-08 | $930.00K 10-Q · filed 2018-11-08 | $703.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $700.00K 10-Q · filed 2018-08-02 | $473.00K derived: sum of 3 quarters · filed 2019-02-28 | -$510.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $587.00K 10-Q · filed 2018-05-09 | $360.00K derived: sum of 2 quarters · filed 2019-02-28 | -$623.00K derived: sum of 3 quarters · filed 2019-02-28 | -$294.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$1.21M derived: sum of 2 quarters · filed 2019-02-28 | -$881.00K derived: sum of 3 quarters · filed 2019-02-28 | -$1.28M 10-K · filed 2019-02-28 |
| 2016-09-30 | -$983.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$654.00K derived: sum of 2 quarters · filed 2017-11-08 | -$1.05M 10-Q · filed 2017-11-08 | $90.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $329.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$66.00K 10-Q · filed 2017-08-09 | $1.07M derived: sum of 3 quarters · filed 2018-02-28 | $1.05M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | -$395.00K 10-Q · filed 2017-05-10 | $744.00K derived: sum of 2 quarters · filed 2018-02-28 | $722.00K derived: sum of 3 quarters · filed 2018-02-28 | $962.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $1.12M derived: sum of 2 quarters · filed 2018-02-28 | $1.36M derived: sum of 3 quarters · filed 2018-02-28 | $1.63M 10-K · filed 2018-02-28 |
| 2015-09-30 | -$22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $218.00K derived: sum of 2 quarters · filed 2016-11-09 | $494.00K 10-Q · filed 2016-11-09 | $256.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $240.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $516.00K 10-Q · filed 2016-08-09 | $278.00K derived: sum of 3 quarters · filed 2017-03-01 | $715.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $276.00K 10-Q · filed 2016-05-10 | $38.00K derived: sum of 2 quarters · filed 2017-03-01 | $475.00K derived: sum of 3 quarters · filed 2017-03-01 | $562.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | -$238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $199.00K derived: sum of 2 quarters · filed 2017-03-01 | $286.00K derived: sum of 3 quarters · filed 2017-03-01 | $90.00K 10-K · filed 2017-03-01 |
| 2014-09-30 | $437.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $524.00K derived: sum of 2 quarters · filed 2015-11-12 | $328.00K 10-Q · filed 2015-11-12 | $76.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | -$109.00K 10-Q · filed 2015-08-13 | -$361.00K derived: sum of 3 quarters · filed 2016-03-11 | $90.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2014-03-31 | -$196.00K 10-Q · filed 2015-05-13 | -$448.00K derived: sum of 2 quarters · filed 2016-03-11 | $3.00K derived: sum of 3 quarters · filed 2016-03-11 | $3.00K derived: sum of 4 quarters · filed 2016-03-11 |
| 2013-12-31 | -$252.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $199.00K derived: sum of 2 quarters · filed 2016-03-11 | $199.00K derived: sum of 3 quarters · filed 2016-03-11 | $199.00K 10-K · filed 2016-03-11 |
| 2013-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $451.00K derived: sum of 2 quarters · filed 2014-11-12 | $451.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $0.00 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-06-24 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |